

## **Data Sheet**

## **Product Information**

Catalog Number	BP10864
Product Name	CHZ868
Description	CHZ868 is a type II JAK2 inhibitor (IC50: 0.17 µM in EPOR JAK2 WT Ba/F3 cell).
Targets&IC50	JAK2: 110 nM
In vitro	CHZ868 is dissolved in DMSO to make 10 mM stock solution and diluted in culture media. Cells are treated with CHZ868 (0, 0.05, 0.1, 0.2 $\mu$ M) or vehicle (DMSO). After 48 hr (Ba/F3 cells) or 72 hr (MHH-CALL4 and PDX cells), CellTiter-Glo Luminescent Cell Viability Assay is added (10 $\mu$ L undiluted or 25 $\mu$ L of a 1:2 dilution in each well) and plates are read.
In vivo	CHZ868 is reconstituted in 0.5% methylcellulose / 0.5% Tween-80 and administered at doses of 10 or 30 mg/kg/day by oral gavage. Pharmacokinetic/pharmacodynamic and efficacy studies in the mouse model of rhEpo-induced polycythemia are carried out essentially. Detection of STAT5 phosphorylation in spleen lysates by Meso Scale Discovery is performed.
CAS No.	1895895-38-1
Chemical Formula	C22H19F2N5O2
Molecular Weight	423.424
Solubility	DMSO: 145 mg/mL (342.45 mM)
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year

Chemical Structure OR Tested Image	HN N N N F F
--	--------------

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

https://www.purduebio.com

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022